GE HealthCare is trading 12.3% up at $72.00 in pre-market trading after reporting better-than-expected second-quarter 2026 results and reaffirming its full-year guidance.
- The company posted $5.3 billion in Q2 revenue, up 5.7% year over year, with EPS rising 16.5% to $1.24 on the back of 3.5% organic growth.
- Management highlighted record organic orders growth of 11.1% and a total backlog of $23.9 billion, which helped fuel the sharp move alongside a broadly stronger healthcare sector.